

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/256988 A1

(51) International Patent Classification:
A61K 47/55 (2017.01)

(21) International Application Number:
PCT/IB2024/055751

(22) International Filing Date:
12 June 2024 (12.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/508,039 14 June 2023 (14.06.2023) US
63/555,128 19 February 2024 (19.02.2024) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85,
Södertälje (SE).

(72) Inventors: **LEE, Esther Cheng Yin**; c/o AstraZeneca
Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437,
Wilmington, Delaware 19850-5437 (US). **GOPALSAMY,
Ariamala**; c/o AstraZeneca Pharmaceuticals LP, 1800
Concord Pike, P.O. Box 15437, Wilmington, Delaware
19850-5437 (US). **SCHNEIDER, Michael**; c/o As-
traZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US).
REICHL, Kyle David; c/o AstraZeneca Pharmaceuticals
LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,
Delaware 19850-5437 (US). **MARCYK, Paul Tomas**; c/o
AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US). **REI-
MANN, Christopher Elias**; c/o AstraZeneca Pharmaceuti-
cals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,
Delaware 19850-5437 (US). **CALIMAN, Alisha Danielle**;
c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike,
P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **WALTON, Laura**; ASTRAZENECA INTELLC-
TUAL PROPERTY, Eastbrook House, Shaftesbury Road,
Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: **SMARCA2 DEGRADERS AND USES THEREOF**



(57) **Abstract:** The present disclosure provides compounds represented by Formula (A), or a pharmaceutically acceptable salt and/or stereoisomer thereof: (A), wherein R^a , R^b , R^7 , R^8 , R^9 , R^{10} , R^{12} , R^{12a} , R^{12b} , R^{12c} , m , X^3 , W , L , and E are as defined in the specification. Compounds represented by Formula (A) are SMARCA2 protein degraders and are thus useful for treating cancer and other diseases.



WO 2024/256988 A1